Trevi Therapeutics (NASDAQ: TRVI)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Trevi Therapeutics (NASDAQ: TRVI) through any online brokerage.
Other companies in Trevi Therapeutics’s space includes: Satsuma Pharmaceuticals (NASDAQ:STSA), Rani Therapeutics Hldgs (NASDAQ:RANI), Anebulo Pharmaceuticals (NASDAQ:ANEB), Endo International (NASDAQ:ENDP) and Milestone Pharmaceuticals (NASDAQ:MIST).
The latest price target for Trevi Therapeutics (NASDAQ: TRVI) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting TRVI to fall to within 12 months (a possible -2.68% downside). 50 analyst firms have reported ratings in the last year.
The stock price for Trevi Therapeutics (NASDAQ: TRVI) is $4.11 last updated August 12, 2022, 8:00 PM UTC.
The next Trevi Therapeutics (TRVI) dividend date is projected to be Thursday, September 1, 2022.
Trevi Therapeutics’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for Trevi Therapeutics.
Trevi Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.